Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.19929 http://scihub22266oqcxt.onion/10.18632/oncotarget.19929 C5610030/?report=reader!5610030!28969098     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncotarget 2017 ; 8 (38): 64607-21 Nephropedia Template TP {{tp|p=28969098|t=2017. CAR-T cell therapy in ovarian cancer: from the bench to the bedside |pdf=|usr=}}{{28969098}} gab.com Text CAR-T cell therapy in ovarian cancer: from the bench to the bedside JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=28969098 #FOAvip Ovarian cancer (OC) is the most lethal gynecological malignancy and is responsible for most gynecological cancer deaths. Apart from conventional surgery, chemotherapy, and radiotherapy, chimeric antigen receptor-modified T (CAR-T) cells as a representative of adoptive cellular immunotherapy have received considerable attention in the research field of cancer treatment. CARs combine antigen specificity and T-cell-activating properties in a single fusion molecule. Several preclinical experiments and clinical trials have confirmed that adoptive cell immunotherapy using typical CAR-engineered T cells for OC is a promising treatment approach with striking clinical efficacy; moreover, the emerging CAR-Ts targeting various antigens also exert great potential. However, such therapies have side effects and toxicities, such as cytokine-associated and ?on-target, off-tumor? toxicities. In this review, we systematically detail and highlight the present knowledge of CAR-Ts including the constructions, vectors, clinical applications, development challenges, and solutions of CAR-T-cell therapy for OC. We hope to provide new insight into OC treatment for the future. Twit Text FOAVip CAR-T cell therapy in ovarian cancer: from the bench to the bedside ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=28969098 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28969098 #FOAvip English Wikipedia <ref>{{Cite pmid|28969098}}</ref> CAR-T cell therapy in ovarian cancer: from the bench to the bedside #MMPMID28969098 Zhu X; Cai H; Zhao L; Ning L; Lang J Oncotarget 2017[Sep]; 8 (38): 64607-21 PMID28969098show ga Ovarian cancer (OC) is the most lethal gynecological malignancy and is responsible for most gynecological cancer deaths. Apart from conventional surgery, chemotherapy, and radiotherapy, chimeric antigen receptor-modified T (CAR-T) cells as a representative of adoptive cellular immunotherapy have received considerable attention in the research field of cancer treatment. CARs combine antigen specificity and T-cell-activating properties in a single fusion molecule. Several preclinical experiments and clinical trials have confirmed that adoptive cell immunotherapy using typical CAR-engineered T cells for OC is a promising treatment approach with striking clinical efficacy; moreover, the emerging CAR-Ts targeting various antigens also exert great potential. However, such therapies have side effects and toxicities, such as cytokine-associated and ?on-target, off-tumor? toxicities. In this review, we systematically detail and highlight the present knowledge of CAR-Ts including the constructions, vectors, clinical applications, development challenges, and solutions of CAR-T-cell therapy for OC. We hope to provide new insight into OC treatment for the future. äCAR-T cell therapy in ovarian cancer: from the bench to the bedside (epmc).pdf DeepDyve Pubget Overpricing